Medscape reports that oral GLP-1 drugs may reshape the obesity treatment landscape, but their true impact remains uncertain. With Novo Nordisk’s oral Wegovy under FDA review and Eli Lilly’s orforglipron showing promising Phase 3 results, experts see new possibilities for patient access, convenience, and cost competition. Yet injectables remain dominant, offering greater efficacy and weekly dosing that many patients prefer. The question lingers: will pills open doors for millions untreated today, or will they complement rather than replace injections?
Keep Reading
Add A Comment